SG11201900298RA - Heterocyclic compound used as fgfr inhibitor - Google Patents
Heterocyclic compound used as fgfr inhibitorInfo
- Publication number
- SG11201900298RA SG11201900298RA SG11201900298RA SG11201900298RA SG11201900298RA SG 11201900298R A SG11201900298R A SG 11201900298RA SG 11201900298R A SG11201900298R A SG 11201900298RA SG 11201900298R A SG11201900298R A SG 11201900298RA SG 11201900298R A SG11201900298R A SG 11201900298RA
- Authority
- SG
- Singapore
- Prior art keywords
- compound
- heterocyclic compound
- fgfr
- compound used
- fgfr inhibitor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/84—Nitriles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Abstract
OF THE DISC LOSURE The present invention relates to a heterocyclic compound, a pharmaceutical composition contain ing the same, a preparation method thereof, and use thereof as a fibroblast growth factor receptor (FGFR) inhibitor . T he compound is a heterocyclic compound as shown in Formula I, or a pharmaceutically acceptable salt, prodrug, solvent compound, polymorph , isomer or stable isotopic derivative thereof . T he present invention further relates to use of the compound for t he treatment or prevention of related diseases which are FGFR - mediated such as cancer, and a method for applying the compound to treat said d iseases. (I)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610550151.3A CN107619388A (en) | 2016-07-13 | 2016-07-13 | Heterocyclic compound as FGFR inhibitor |
PCT/CN2017/088038 WO2018010514A1 (en) | 2016-07-13 | 2017-06-13 | Heterocyclic compound used as fgfr inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201900298RA true SG11201900298RA (en) | 2019-02-27 |
Family
ID=60951887
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201900298RA SG11201900298RA (en) | 2016-07-13 | 2017-06-13 | Heterocyclic compound used as fgfr inhibitor |
SG10202013038VA SG10202013038VA (en) | 2016-07-13 | 2017-06-13 | Heterocyclic compound used as fgfr inhibitor |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10202013038VA SG10202013038VA (en) | 2016-07-13 | 2017-06-13 | Heterocyclic compound used as fgfr inhibitor |
Country Status (12)
Country | Link |
---|---|
US (1) | US10590109B2 (en) |
EP (1) | EP3489223A4 (en) |
JP (1) | JP6896852B2 (en) |
KR (1) | KR102386428B1 (en) |
CN (2) | CN107619388A (en) |
AU (1) | AU2017295628B2 (en) |
CA (1) | CA3030070A1 (en) |
MX (1) | MX2019000451A (en) |
PH (1) | PH12019500036A1 (en) |
RU (1) | RU2742485C2 (en) |
SG (2) | SG11201900298RA (en) |
WO (1) | WO2018010514A1 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3069602C (en) * | 2017-08-04 | 2022-12-06 | Abbisko Therapeutics Co., Ltd. | Formylpyridine derivative having fgfr4 inhibitory activity, preparation method therefor and use thereof |
AU2018346597B2 (en) | 2017-10-06 | 2023-07-13 | Forma Therapeutics, Inc. | Inhibiting Ubiquitin Specific Peptidase 30 |
CN108129471A (en) * | 2018-03-20 | 2018-06-08 | 韩邦森 | A kind of synthesis technology of thiazole substituted uracil compound |
BR112021003620A2 (en) | 2018-10-05 | 2021-05-18 | Forma Therapeutics, Inc. | Fused pyrrolines that act as specific protease inhibitors for ubiquitin 30 (usp30) |
KR20210142154A (en) | 2019-03-21 | 2021-11-24 | 옹쎄오 | DBAIT molecules in combination with kinase inhibitors for the treatment of cancer |
CA3159348A1 (en) | 2019-11-08 | 2021-05-14 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
CN111039874B (en) * | 2019-12-13 | 2022-11-04 | 南开大学 | Zero-wastewater preparation method of 2-amino-4-methylpyrimidine compound |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2340605C2 (en) * | 2002-06-27 | 2008-12-10 | Ново Нордиск А/С | Arylcarbonyl derivatives as therapeutic agents |
CN1508130A (en) * | 2002-12-18 | 2004-06-30 | 中国科学院大连化学物理研究所 | N-phenyl-N'-pyrimidinyl-substituted urea derivative synthesizing method |
FR2850652B1 (en) * | 2003-01-31 | 2008-05-30 | Aventis Pharma Sa | NOVEL CYCLIC UREA DERIVATIVES, THEIR PREPARATION AND THEIR PHARMACEUTICAL USE AS INHIBITORS OF KINASES |
ATE400567T1 (en) * | 2004-06-23 | 2008-07-15 | Lilly Co Eli | KINASE INHIBITORS |
GB0512324D0 (en) * | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
FR2889526B1 (en) * | 2005-08-04 | 2012-02-17 | Aventis Pharma Sa | SUBSTITUTED 7-AZA-INDAZOLES, COMPOSITIONS CONTAINING SAME, PROCESS FOR PRODUCTION AND USE |
EP1790342A1 (en) * | 2005-11-11 | 2007-05-30 | Zentaris GmbH | Pyridopyrazine derivatives and their use as signal transduction modulators |
US20070173488A1 (en) * | 2005-11-16 | 2007-07-26 | Sgx Pharmaceuticals, Inc. | Pyrazolothiazole Protein Kinase Modulators |
AU2006320440B2 (en) * | 2005-12-02 | 2012-04-05 | Bayer Healthcare Llc | Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis |
FR2908409B1 (en) * | 2006-11-10 | 2009-01-09 | Sanofi Aventis Sa | SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING SAME, PROCESS FOR PRODUCTION AND USE |
FR2947546B1 (en) * | 2009-07-03 | 2011-07-01 | Sanofi Aventis | PYRAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION |
WO2013024427A1 (en) * | 2011-08-16 | 2013-02-21 | Glenmark Pharmaceuticals S.A. | Novel urea derivatives as tec kinase inhibitors and uses thereof |
CA2927252C (en) * | 2013-10-25 | 2021-09-28 | Novartis Ag | Ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors |
BR112017016817A2 (en) * | 2015-03-25 | 2018-04-03 | Novartis Ag | heterocyclic derivatives formulated as fgfr4 inhibitors |
US9802917B2 (en) | 2015-03-25 | 2017-10-31 | Novartis Ag | Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide |
-
2016
- 2016-07-13 CN CN201610550151.3A patent/CN107619388A/en active Pending
-
2017
- 2017-06-13 CA CA3030070A patent/CA3030070A1/en active Pending
- 2017-06-13 JP JP2019523154A patent/JP6896852B2/en active Active
- 2017-06-13 EP EP17826852.0A patent/EP3489223A4/en not_active Withdrawn
- 2017-06-13 SG SG11201900298RA patent/SG11201900298RA/en unknown
- 2017-06-13 CN CN201780002825.9A patent/CN108349896B/en active Active
- 2017-06-13 KR KR1020197004058A patent/KR102386428B1/en active IP Right Grant
- 2017-06-13 WO PCT/CN2017/088038 patent/WO2018010514A1/en unknown
- 2017-06-13 MX MX2019000451A patent/MX2019000451A/en unknown
- 2017-06-13 SG SG10202013038VA patent/SG10202013038VA/en unknown
- 2017-06-13 AU AU2017295628A patent/AU2017295628B2/en not_active Ceased
- 2017-06-13 RU RU2019100164A patent/RU2742485C2/en active
-
2019
- 2019-01-04 PH PH12019500036A patent/PH12019500036A1/en unknown
- 2019-01-11 US US16/246,236 patent/US10590109B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
RU2019100164A (en) | 2020-08-13 |
CN108349896A (en) | 2018-07-31 |
MX2019000451A (en) | 2019-09-27 |
CA3030070A1 (en) | 2018-01-18 |
AU2017295628B2 (en) | 2021-05-13 |
US10590109B2 (en) | 2020-03-17 |
RU2019100164A3 (en) | 2020-08-27 |
AU2017295628A1 (en) | 2019-02-21 |
KR20190032420A (en) | 2019-03-27 |
KR102386428B1 (en) | 2022-04-14 |
CN108349896B (en) | 2021-06-01 |
EP3489223A1 (en) | 2019-05-29 |
PH12019500036A1 (en) | 2019-10-28 |
EP3489223A4 (en) | 2020-01-15 |
JP6896852B2 (en) | 2021-06-30 |
JP2019522055A (en) | 2019-08-08 |
US20190144427A1 (en) | 2019-05-16 |
WO2018010514A1 (en) | 2018-01-18 |
SG10202013038VA (en) | 2021-01-28 |
CN107619388A (en) | 2018-01-23 |
RU2742485C2 (en) | 2021-02-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201900298RA (en) | Heterocyclic compound used as fgfr inhibitor | |
PH12019500395A1 (en) | Amino-pyrrolopyrimidinone compounds and methods of use thereof | |
PH12018500360A1 (en) | Heteroaryl derivatives as parp inhibitors | |
EA201891191A1 (en) | 2-SUBSTITUTED HINAZOLIN COMPOUNDS CONTAINING A SUBSTITUTED HETEROCYCLIC GROUP AND METHODS OF THEIR APPLICATION | |
EA201992126A1 (en) | JAK INHIBITORS CONTAINING 4-MEMBER HETEROCYCLIC AMIDE | |
MY195427A (en) | Jak Kinase Inhibitor Compounds for Treatment of Respiratory Disease | |
MX2019003143A (en) | Alkynyl-substituted heterocyclic compound, preparation method therefor and medical use thereof. | |
WO2015200481A8 (en) | Mnk inhibitors and methods related thereto | |
WO2015168466A8 (en) | Inhibitors of lysine specific demethylase-1 | |
MY197116A (en) | Bicyclic heterocyclyl derivatives as irak4 inhibitors | |
EA202090413A1 (en) | Pyrazole and triazobicyclic compounds as inhibitors of JAK kinases | |
MX2020013694A (en) | Heterocyclic compound as trk inhibitor. | |
EA202190681A1 (en) | DIMETHYLAMINOAZETIDINE AMIDES AS JAK INHIBITORS | |
MY188700A (en) | Bicyclic ketone sulfonamide compounds | |
MX369369B (en) | Quinolone derivatives as fibroblast growth factor receptor inhibitors. | |
MX2016016530A (en) | Phosphatidylinositol 3-kinase inhibitors. | |
PH12021550825A1 (en) | Quinoline derivatives as alpha4beta7 integrin inhibitors | |
WO2015191754A3 (en) | Phosphatidylinositol 3-kinase inhibitors | |
EA202190686A1 (en) | 5-7-MEMBER HETEROCYCLIC AMIDES AS JAK INHIBITORS | |
MX2020001531A (en) | Novel heterocyclic compounds as cdk8/19 inhibitors. | |
EA201991355A1 (en) | IMIDAZO [1,5-A] PYRASINE DERIVATIVES AS PI3K DELTA INHIBITORS | |
SA520411787B1 (en) | Benzimidazole derivatives and their uses | |
EA201990678A1 (en) | Heteroarylcarboxamide Compounds as Ripk2 Inhibitors | |
PH12017500007A1 (en) | Quinolizinone derivatives as p13k inhibitors | |
EP4252856A3 (en) | Novel quinazolinones that inhibit the formation of tau oligomers and their method of use |